SLCO1B3 and tuberculosis: GCDCA-S has been proved to be underlying diagnosis biomarkers for tuberculosis, severity of patients with acute hepatitis E infection (Deng et al., 2021; Wu et al., 2022), as well as the promising surrogate markers for quantitatively evaluating potential drug-drug interactions mediated by OATP1B (such as Rifampicin), OATP1B3 (such as micafungin), and Oatps-mediated hepatic uptake of atorvastatin (Takehara et al., 2018; Jin et al., 2022; Ma et al., 2021).